Medication or procedure

Many people have heard a tidy story in which medications merely manage symptoms while procedures fix the underlying problem. The story is memorable, and the evidence does not support it.

Current work places GLP-1 receptor agonists and bariatric surgery in the same mechanistic category, differing in degree rather than kind.C-IV-09 ESG, which is an endoscopic procedure, is neither of those, and no study extends that comparison to it. What can be said is narrower: all of these act on appetite-related physiology, through different levers. Neither has been shown to reset a defended weight in humans. The Endocrine Society's scientific statement describes such therapies as having the potential to reset the defended level, which is an aspiration rather than a result.C-III-02

The models that best fit the human evidence explicitly permit a new, lower stable weight.C-III-08 Both options are attempts to reach it, and they differ in how they act, for how long, and at what cost.

A GLP-1 medication copies a satiety hormone your gut already makes, engineered to act more strongly and to last far longer than the natural version. Appetite falls, often substantially.C-IV-07

ESG reshapes the stomach from the inside so that it holds less and empties more slowly, with half-emptying at about 152 minutes against 89 in controls, a difference still measurable at twelve months.C-IV-05

The levers are different, but both act on the same appetite-related physiology.

With medication, the effect continues only while treatment continues. After 68 weeks of treatment, at about 17% below starting weight, participants who stopped regained roughly two-thirds of the loss within a year.C-III-09 That is not a failure of the drug but a property of the approach, since the effect depends on the signal being maintained. The practical question is whether long-term, possibly indefinite, treatment is something you want and can afford.

With a procedure, the intervention is front-loaded. There is one event, a recovery, and a change that does not depend on remembering a weekly dose. In exchange, you accept about a 2.2% chance of a serious complicationC-IV-12, and you accept that the strongest evidence is weaker than the headline figures suggest: in the one sham-controlled trial, which enrolled 40 MASH patients and ran for 72 weeks, the ESG arm lost 9.5% against 3.9% for sham.C-IV-03

Neither option escapes the underlying biology. In the one study that measured it, weight loss raised appetite by roughly 100 calories a day for each kilogram lostC-III-06. Substantial weight loss by any route also takes some lean tissue with itC-IV-08 whichever option you choose, so resistance training, which preserves lean mass, belongs alongside the treatment rather than in place of it.

• What happens if I stop the medication, and is stopping part of the plan?
• What is my BMI, and does it fall within the authorized range for the procedure?
• What does each option cost over five years rather than one?
• What is the plan for protecting muscle with either option?
• What happens if I regain?

If a clinician answers any of these with a single number and no caveat, it is reasonable to ask where the number comes from.